NCT00801294 2017-12-29
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
Clinical Trials
7 trialsNCT02182063 2017-12-28
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01004003 2017-10-26
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 2 Completed
NCT00710762 2016-08-15
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00987935 2016-03-10
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Boehringer Ingelheim
Phase 2 Completed
NCT00904839 2015-02-04
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00706628 2015-01-15
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed